- Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise
- Newly licensed technologies include use of Genprex’s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy
Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes, announced that the Company and a major cancer research center in Houston, Texas, in March 2021, entered into an amendment to their May 2020 License Agreement to grant to Genprex an exclusive worldwide license to an additional portfolio of six patents and one patent application and related technology. The Newly Licensed IP includes methods for treating non-small cell lung cancer (NSCLC) by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies, in patients who are predicted to be responsive to TUSC2 therapy. A TUSC2 gene-expressing plasmid is the active agent in REQORSA™ immunogene therapy, Genprex’s lead drug candidate.
“We are pleased to continue optimizing and expanding our world-class intellectual property portfolio with the addition of these technologies,” said Rodney Varner, President and Chief Executive Officer of Genprex. “These new technologies further add to our arsenal of combination therapies for REQORSA, and may enable us to improve patient outcomes through the advancement of multiple therapeutic approaches.”
